A5051560810- Biochemical and Molecular Research
- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Genomics and Phylogenetic Studies
- Enzyme Production and Characterization
- Microbial Natural Products and Biosynthesis
Universidade de São Paulo
2017-2023
Instituto Butantan
2018
Dihydrofolate reductase (DHFR), a key enzyme involved in folate metabolism, is widely explored target the treatment of cancer, immune diseases, bacteria, and protozoa infections. Although several antifolates have proved successful infectious they been underexplored to combat tuberculosis, despite essentiality M. tuberculosis DHFR (MtDHFR). Herein, we describe an integrated fragment-based drug discovery approach MtDHFR that has identified hits with scaffolds not yet any previous design...
Tuberculosis is a disease caused by Mycobacterium tuberculosis and the leading cause of death from single infectious pathogen, with high prevalence in developing countries Africa Asia. There still need for development or repurposing novel therapies to combat this owing long-term nature current because number reported resistant strains. Here, structures dihydrofolate reductase M. (MtDHFR), which key target folate pathway, are complex four antifolates, pyrimethamine, cycloguanil, diaverdine...
Dihydrofolate reductase (DHFR) is a key enzyme involved in the folate pathway that has been heavily targeted for development of therapeutics against cancer and bacterial protozoa infections amongst others. Despite being an essential Mycobacterium tuberculosis (Mtb) viability, DHFR remains underexploited target (TB) treatment. Herein, we report preparation evaluation series compounds Mtb (MtbDHFR). The have designed using merging strategy traditional pyrimidine-based antifolates with...
Abstract Dihydrofolate reductase (DHFR), a key enzyme involved in folate metabolism, is widely explored target the treatment of cancer, immune diseases, bacteria and protozoa infections. Although several antifolates have proved successful infectious none been developed to combat tuberculosis, despite essentiality M. tuberculosis DHFR (MtDHFR). Herein, we describe an integrated fragment-based drug discovery approach MtDHFR that has identified hits with scaffolds not yet any previous design...